PREVENTING NEUTRALIZING ANTIBODY FORMATION IN MS PATIENTS WITH SC IFN-β-AL

预防 SC IFN- 多发性硬化症患者中和抗体的形成

• 批准号: 7606036
• 负责人: GARETH PARRY
• 金额: $ 0.15万
• 依托单位: UNIVERSITY OF MINNESOTA
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-12-01 至 2007-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7606036
• 关键词: Antibodies; Antibody Formation; Computer Retrieval of Information on Scientific Projects Database; Development; Effectiveness; Funding; Grant; Institution; Interferon-beta; Methylprednisolone; Patients; Relapsing-Remitting Multiple Sclerosis; Research; Research Personnel; Resources; Source; Steroids; Therapeutic Effect; Thinking; United States National Institutes of Health; avonex; improved; neutralizing antibody; prevent

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Interferon-beta (IFN-beta; e.g., Rebif) is the most frequently used first-line treatment for relapsing-remitting multiple sclerosis (RRMS). Several studies have shown that the use of IFN-beta produces neutralizing antibodies (NAbs) in a significant proportion of MS patients, which are thought to decrease the bio-availability of IFN-beta and reduce its therapeutic effects. This study will examine whether the addition of steroids (methylprednisolone; MP) to the treatment regime will prevent or decrease the development of antibodies, thus improving the effectiveness of Rebif.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 干扰素β（IFN-BETA;例如，Rebif）是最常用的一线治疗方法，用于复发复发多发性硬化症（RRMS）。几项研究表明，IFN-β的使用会在很大一部分的MS患者中产生中和抗体（NABS），这被认为可以降低IFN-β的生物可用性并降低其治疗作用。这项研究将检查在治疗方案中添加类固醇（甲基丙糖酮； MP）是否会预防或减少抗体的发育，从而提高Rebif的有效性。